IFNAR1 and COVID-19: How anti-IFNAR1 therapy affects the risk of COVID-19 and its complications is not known, but numerous data support that lacking capacity to rapidly induce a IFN-I response is a crucial risk factor for severe COVID-19 (85), although type III IFN also seem to be important (86).